Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 4/20/2017 |
| Start Date: | September 7, 2016 |
| End Date: | October 28, 2016 |
A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers
This study is intended to determine whether the addition of trospium chloride to xanomeline
tartrate will ameliorate the peripheral cholinergic side effects that have been previously
experienced with xanomeline tartrate when administered alone.
tartrate will ameliorate the peripheral cholinergic side effects that have been previously
experienced with xanomeline tartrate when administered alone.
In this inpatient study, volunteers will received either xanomeline alone, or xanomeline
plus trospium for 7 days. Subjects will report cholinergic side effects daily via visual
analog scales, for each of nausea, vomiting, diarrhea, sweating and excessive salivation.
Clinician administered scales will also be administered daily for assessment of the same
cholinergic side effects.
plus trospium for 7 days. Subjects will report cholinergic side effects daily via visual
analog scales, for each of nausea, vomiting, diarrhea, sweating and excessive salivation.
Clinician administered scales will also be administered daily for assessment of the same
cholinergic side effects.
Inclusion Criteria:
- Female subjects must be postmenopausal (at least 2 years prior to dosing) or agree to
use an acceptable form of birth control from screening until 14 days after completion
of the study. If on birth control pills, have been on a stable dose for≥12 months.
- Good general health
- Ability to give informed consent and understand verbal instructions
- Willingness to spend 10 days in an in-patient facility
Exclusion Criteria:
- History or presence of clinically significant cardiovascular, pulmonary, hepatic,
renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
neurologic, oncologic, or psychiatric disease or any other condition that, in the
opinion of the Investigator, would jeopardize the safety of the subject or the
validity of the study results. (Subjects with any history of resolved cancer that is
>5 years passed can be included.)
- Body Mass Index <18 or > 40 kg/m2
- History of or high risk of urinary retention, gastric retention, or narrow-angle
glaucoma
- History of alcohol or drug abuse within the last 24 months, or current abuse as
determined by urine toxicology screen
- Clinically significant abnormal finding on the physical exam, medical history, ECG,
or clinical laboratory results at screening
- Has participated in another clinical trial within 90 days prior to the first dose of
study medication
- Needs to take any prescription medication besides the investigational product or
those specifically noted above.
Use of any vitamins, herbs, supplements, or over the counter medications are excluded
within one week of enrollment, and during the course of the trial. Specifically, subjects
may not take Benadryl® for one week prior and during the course of the study.
- Use of any tobacco products within the past 30 days
- Previous positive test for HIV 1 and/or 2, or Hepatitis A, B, or C, or a positive
test obtained at screening.
We found this trial at
1
site
